Takotsubo syndrome in a patient treated with sunitinib for renal cancer

Journal of Clinical Oncology

Volumn 30, Issue 24, 2012, Pages

  Numico, Gianmauro ^a   Sicuro, Marco ^a   Silvestris, Nicola ^b   Mozzicafreddo, Alessandro ^a   Trogu, Antonio ^a   Malossi, Alessandra ^a   Cristofano, Antonella ^a   Thiebat, Benedetta ^a  

^a Ospedale U Parini   (Italy)

^b NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DALTEPARIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EVEROLIMUS; LOW MOLECULAR WEIGHT HEPARIN; SUNITINIB; THYROXINE; TROPONIN T;

ADULT; ARTICLE; CANCER PATIENT; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG DOSE REDUCTION; DYSPNEA; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAM; FATIGUE; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; HYPOKINESIA; INTRACARDIAC THROMBOSIS; KIDNEY CARCINOMA; KIDNEY SURGERY; MEDIASTINUM LYMPH NODE; MEDIASTINUM TUMOR; MITRAL VALVE REGURGITATION; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RASH; SUBCLINICAL HYPOTHYROIDISM; SYSTOLIC HEART MURMUR; TAKOTSUBO CARDIOMYOPATHY; THORAX PAIN;

ADENOCARCINOMA, CLEAR CELL; FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; MIDDLE AGED; PYRROLES; TAKOTSUBO CARDIOMYOPATHY;

EID: 84865229668     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2012.42.4911     Document Type: Article

References (18)

1. Gianni M, Dentali F, Grandi AM, et al: Apical ballooning syndrome or takotsubo cardiomyopathy: A systematic review. Eur Heart J 27:1523-1529, 2006 (Pubitemid 43954909)
2. Golabchi A, Sarrafzadegan N: Takotsubo cardiomyopathy or broken heart syndrome: A review article. J Res Med Sci 16:340-345, 2011
3. Pernicova I, Garg S, Bourantas CV, et al: Takotsubo cardiomyopathy: A review of the literature. Angiology 61:166-173, 2010
4. Grunwald MR, Howie L, Diaz LA Jr: Takotsubo cardiomyopathy and fluorouracil: Case report and review of the literature. J Clin Oncol 30:e11-e14, 2012
5. Radhakrishnan V, Bakhshi S: 5-Fluorouracil-induced acute dilated cardiomyopathy in a pediatric patient. J Pediatr Hematol Oncol 33:323, 2011
6. Basselin C, Fontanges T, Descotes J, et al: 5-Fluorouracil-induced Tako-Tsubo-like syndrome. Pharmacotherapy 31:226, 2011
7. Cheriparambil KM, Vasireddy H, Kuruvilla A, et al: Acute reversible cardiomyopathy and thromboembolism after cisplatin and 5-fluorouracil chemotherapy - A case report. Angiology 51:873-878, 2000
8. Stewart T, Pavlakis N, Ward M: Cardiotoxicity with 5-fluorouracil and capecitabine: More than just vasospastic angina. Intern Med J 40:303-307, 2010
9. Gianni M, Dentali F, Lonn E: 5 flourouracil-induced apical ballooning syndrome: A case report. Blood Coagul Fibrinolysis 20:306-308, 2009
10. Kobayashi N, Hata N, Yokoyama S, et al: A case of Takotsubo cardiomyopathy during 5-fluorouracil treatment for rectal adenocarcinoma. J Nihon Med Sch 76:27-33, 2009
11. Lim TJ, Lee JH, Chang SG, et al: Life-threatening complications associated with the tyrosine kinase inhibitor sunitinib malate. Urol Int 85:475-478, 2010
12. Schutz FA, Je Y, Richards CJ, et al: Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitors. J Clin Oncol 30:871-877, 2012
13. Chu TF, Rupnick MA, Kerkela R, et al: Cardiotoxicity associated with the tyrosine kinase inhibitor sunitinib. Lancet 370:2011-2019, 2007 (Pubitemid 350236338)
14. Telli ML, Witteles RM, Fisher GA, et al: Cardiotoxicity associated with the cancer therapeutic agent sunitinib malate. Ann Oncol 19:1613-1618, 2008
15. Khakoo AY, Kassiotis CM, Tannir N, et al: Heart failure associated with sunitinib malate: A multitargeted receptor tyrosine kinase inhibitor. Cancer 112:2500-2508, 2008
16. Di Lorenzo G, Autorino R, Bruni G, et al: Cardiovascular toxicity following sunitinib therapy in metastatic renal cell carcinoma: A multicenter analysis. Ann Oncol 20:1535-1542, 2009
17. Cheng H, Force T: Why do kinase inhibitors cause cardiotoxicity and what can be done about it? Prog Cardiovasc Dis 53:114-120, 2010
18. Vaklavas C, Lenihan D, Kurzrock R, et al: Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: What are the important clinical markers to target? The Oncologist 15:130-141, 2010